News

As part of a research and license agreement, Astellas Pharma will be able to use Xencor’s bispecific technology to advance a novel bispecific antibody program in oncology. The

QUE Oncology is developing drugs for large unmet medical needs and has already advanced clinical development of its lead drug program Q-122, through four Phase 1 trials. QUE

Data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) levels across the four dosage cohorts. Eight patients total were dosed. Based

In this connection, the regulator approved the company’s Investigational New Drug (IND) application to begin the early stage trial for UCARTCS1. The allogeneic CAR-T therapy is based on

IFM Tre, which was launched in July 2018, is currently developing a suite of NLRP3 antagonists for the treatment of inflammatory diseases. NLRP3, which expands to NOD-, LRR-

The designation has been provided based on Phase II data from the Sprint trial, which evaluated selumetinib as an oral monotherapy in pediatric patients aged three years or

In September 2018 the European Commission granted marketing authorization for NERLYNX (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast

AJOVY is a humanized monoclonal antibody (mAb) that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor. AJOVY is the first and

The early-stage trial is assessing the safety and efficacy of the ipatasertib combination in patients with locally advanced or metastatic triple-negative breast cancer who previously did not receive